Lyell Immunopharma/$LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Ticker
$LYEL
Sector
Primary listing
Employees
161
Headquarters
Website
LYEL Metrics
BasicAdvanced
$292m
-
-$13.06
-0.06
-
Price and volume
Market cap
$292m
Beta
-0.06
52-week high
$45.00
52-week low
$8.46
Average daily volume
105k
Financial strength
Current ratio
7.235
Quick ratio
6.875
Long term debt to equity
14.429
Total debt to equity
17.851
Profitability
EBITDA (TTM)
-176.04
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-794,858.06%
Operating margin (TTM)
-601,516.13%
Management effectiveness
Return on assets (TTM)
-29.87%
Return on equity (TTM)
-80.76%
Valuation
Price to revenue (TTM)
7,624.848
Price to book
1.07
Price to tangible book (TTM)
1.07
Price to free cash flow (TTM)
-1.758
Free cash flow yield (TTM)
-56.89%
Free cash flow per share (TTM)
-7.122
Growth
Revenue change (TTM)
-52.31%
Earnings per share change (TTM)
-46.98%
3-year revenue growth (CAGR)
-92.83%
3-year earnings per share growth (CAGR)
-3.76%
LYEL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs